The DOI matches its Crossref record; 51 of the 55 references it cites were found in a registry or an index; 17 of the 35 sources its claims cite were checked for support.
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer
Abstract
Background Recent therapeutic strategies for KRAS-mutated cancers that inhibit the MAPK pathway have attracted considerable attention. The RAF/MEK clamp avutometinib (VS-6766/CH5126766/RO5126766/CKI27) is promising for patients with KRAS-mutated cancers. Although avutometinib monotherapy has shown clinical activity in patients with KRAS-mutated cancers, effective combination strategies will be important to develop. Methods Using a phosphorylation kinase array kit, we explored the feedback mechanism of avutometinib in KRAS-mutated NSCLC cells, and investigated the efficacy of combining avutometinib with inhibitors of the feedback signal using in vitro and in vivo experiments. Moreover, we searched for a biomarker for the efficacy of combination therapy through an in vitro study and analysis using the The Cancer Genome Atlas Programme dataset. Results Focal adhesion kinase (FAK) phosphorylation/activation was increased after avutometinib treatment and synergy between avutometinib and FAK inhibitor, defactinib, was observed in KRAS-mutated NSCLC cells with an epithelial rather than mesenchymal phenotype. Combination therapy with avutometinib and defactinib induced apoptosis with upregulation of Bim in cancer cells with an epithelial phenotype in an in vitro and in vivo study. Conclusions These results demonstrate that the epithelial-mesenchymal transition status may be a promising biomarker for the efficacy of combination therapy with avutometinib and defactinib in KRAS-mutated NSCLC.
Overview
CoChat Summary
## TL;DR
Avutometinib activates a FAK/AKT bypass and reactivates ERK in KRAS-mutated NSCLC cells, and adding the FAK inhibitor defactinib is synergistic mainly in epithelial-phenotype cells. The paper argues that EMT status is a practical biomarker for response to the avutometinib + defactinib combination.
## Key findings
- In NCI-H358 cells, avutometinib at concentrations above 1.5 µmol/L for 72 h left ~45% of cells surviving, and pFAK increased after 72 h of treatment.
- In NCI-H2122 and NCI-H358 cells, ERK phosphorylation was strongly inhibited at 3 h but reactivated at 72 h, while FAK and AKT phosphorylation increased over 72 h.
- Across nine KRAS-mutated NSCLC cell lines, the combination index (CI) for avutometinib + defactinib was <0.7 in 3 lines: NCI-H358, NCI-H2122, and NCI-H441; other lines were between 0.7 and 1.2.
- EMT score correlated strongly with combination response, with a reported positive correlation of R² = 0.7937 between EMT score and CI value; the paper states that CI values above 0.7 corresponded to a stronger mesenchymal state.
- In vivo, combination therapy maintained tumour suppression after treatment cessation, and the mean tumour weight was significantly lower than with avutometinib alone (p = 0.029). In the CDX model, the combination group had fewer Ki-67-positive cells and more TUNEL-positive cells than the avutometinib-alone group (p < 0.001 for both).
## Methods
- Nine KRAS-mutated human NSCLC cell lines were studied in vitro; the paper also used an NCI-H358 cell-line-derived xenograft model in female BALB/c nu/nu mice (n = 6 per group).
- The authors used RTK phosphorylation arrays, western blotting, CCK-8 viability assays, colony formation, siRNA knockdown of FAK and MYC, qRT-PCR for IGF-1, flow cytometry for cell cycle/apoptosis, scratch assays, and in vivo IHC/TUNEL analyses.
- EMT status was assessed by western blotting for epithelial/mesenchymal markers and by GSVA of RNA-seq data from the Cell Model Passports database using epithelial and mesenchymal gene sets; drug interaction was quantified with CompuSyn combination index analysis.
## Limitations
- The paper explicitly says that further clinical investigations are needed to validate EMT status as a biomarker for combination therapy.
- The data availability statement says the supporting data are available from the authors upon reasonable request, which limits immediate reproducibility/access.
- Evident from the text: the main mechanistic and biomarker conclusions are based on cell lines and one mouse xenograft model, so clinical generalizability to patients is not directly established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 1 Not valid · 5 Not checked · 76 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
What the sources say
- Not checked — no full text of the sourcecites [11] Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25:697–710. source
- Not checked — no full text of the sourcecites [12] Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15:577–92. source
- Supportedcites [13] Lake D, Corrêa SA, Müller J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci. 2016;73:4397–413. source
The section on resistance to ERK1/2 pathway inhibitors says that reactivation of ERK1/2 signalling is a main reason for resistance to B-Raf or MEK1/2 inhibitors. Figure 3 explains the proposed mechanism: inhibition weakens negative feedback, increasing signal flux and ERK1/2 activity and requiring higher inhibitor doses. Page numbers are not provided in our copy. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Meanwhile, defactinib monotherapy was not suf fi ciently effective in patients with KRASmutated NSCLC [29].”
What the sources say
- Supportedcites [29] Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 2020;139:60–67. source
The Conclusions (section 5.0) state that single-agent defactinib had only modest activity in KRAS-mutant NSCLC and suggest that future studies focus on multidrug regimens. This supports the citing sentence's characterization of monotherapy as insufficiently effective; the trial enrolled previously treated patients with advanced disease. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Avutometinib also signi fi cantly increased the IGF-1 mRNA levels in NCI-H358 and NCI-H2122 cells (Fig. 1e).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Regarding the cell growth and cell cycle, TGFβ -induced EMT slowed down cell growth and increased the percentage of cells in the G0-G1 phase (Fig. 4c, d).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Focal adhesion kinase (FAK) phosphorylation/activation was increased after avutometinib treatment”
- Also stated in: § Dual RAF/MEK inhibitor avutometinib activates FAK and AKT and reactivates ERK · plain
“The phosphorylation of FAK (pFAK) increased after 72 h of treatment with avutometinib (Fig. 1a).”
plainstates a causen = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Dual RAF/MEK inhibitor avutometinib activates FAK and AKT and reactivates ERK · plain
51 more claims
Create a free account to see all 95 claims and every source verdict.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 16
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gene set variation analysis (GSVA) of cell lines using the epithelial and mesenchymal gene signature set
“For each cell line (one expression data point), we computed two scores using epithelial (288 genes) and mesenchymal (188 genes) gene lists [22].”
§ 364
“These scores were based on GSVA using a list of 228 epithelial genes and 188 mesenchymal genes as signature gene sets [22].”
Citations
Cites
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Signaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721
Integrin-regulated FAK–Src signaling in normal and cancer cells
Mitra, S. K., & Schlaepfer, D. D. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.011 · Cited by 1,590
pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions.
Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., & Parsons, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.5192 · Cited by 1,444
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin.
Hanks, S. K., Calalb, M. B., Harper, M. C., & Patel, S. K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8487 · Cited by 818
Cited by
EMT and cancer: what clinicians should know
Thompson, E. W., Redfern, A. D., Brabletz, S., Berx, G., Agarwal, V., Ganesh, K., Huang, R. Y., Ishay-Ronen, D., Savagner, P., Sheng, G., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01058-2 · Cited by 83
“• Expression of EMT markers in samples from patients with NSCLC receiving chemoradiotherapy is positively correlated with disease relapse 245 .”
InfluentialAvutometinib and Defactinib: First Approval
Blair, H. A. (2025) · Drugs · doi:10.1007/s40265-025-02215-8 · Cited by 27
Angeli, S., Neophytou, C., Kalli, M., Stylianopoulos, T., & Mpekris, F. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1564626 · Cited by 41
Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
Hartwich, T. M. P., Mansolf, M., Demirkiran, C., Greenman, M. P., Bellone, S., McNamara, B. C., Nandi, S. P., Alexandrov, L. B., Yang‐Hartwich, Y., Coma, S., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70210 · Cited by 17
“12,33,34 Consistent with this view, the combination of avutometinib with defactinib is currently being evaluated in a multicenter, randomized, open-label, Phase 2 study of patients with molecularly profiled recurrent LGSOC in ENGOT-ov60/GOG-3052/RAMP 201 (NCT04625270).”
BackgroundAlmazan, J. D., Turapov, T., Kircher, D. A., Stanley, K. A., Culver, K. M., Medellin, A. P., Field, M. N., Parkman, G. L., Colman, H., Coma, S., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101943 · Cited by 20
Metadata
- Authors
- Yoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T.
- Affiliations
- Kyoto Prefectural University of Medicine (JP)
- Corresponding author
- Horinaka, Mano
- ORCID
- Venue
- British Journal of Cancer
- Published
- 2024-05-31
- Volume
- 131
- Issue
- 2
- Pages
- 361-371
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W4399201891
- Cited by
- 15
- References
- 55
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 2
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- British Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- the Public Promoting Association Asano Foundation for Studies on Medicine
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- epithelial-mesenchymal transition, avutometinib, defactinib, KRAS mutation, non-small cell lung cancer, MAPK signaling, focal adhesion kinase, FAK inhibitors, combination therapy, biomarkers, apoptosis, building information modeling, feedback signaling
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Mutation, Phosphorylation, Pyrazines, Sulfonamides, Biomarkers, Tumor, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Focal Adhesion Kinase 1, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-03, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-03 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41416-024-02727-2
- The paper
- Yoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024). Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-024-02727-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.